Short-term administration of selected anti-T-cell receptor V beta chain specific MoAb reduces sialadenitis in MRL/lpr mice.
Sialadenitis develops spontaneously in MRL/Mp mice bearing a lymphoproliferative gene, lpr (MRL/Mp-lpr/lpr). Based on recent observations of an oligoclonal expansion of T-cell receptor (TCR) expressing V beta chain families (V beta 4, V beta 8.1,2, V beta 10b) in salivary glands of these mice we have initiated selective antibody therapy. Treatment with monoclonal antibodies (MoAb) specific for T cells expressing a mixture of TCR V beta 4, V beta 8.1,2 and V beta 10b was applied to MRL/lpr mice before and after the spontaneous development of sialadenitis. The in vivo treatment with V beta 4, V beta 8.1,2 and V beta 10b MoAb did not prevent the development of sialadenitis. However, in animals with established sialadenitis, treatment with the MoAb significantly decreased the inflammation compared with the control groups. Immunohistochemical staining of cell phenotypes demonstrated a change in the ratio of CD4/CD8 in the animals with established sialadenitis. Altogether, these findings illustrate that it is possible to modulate sialadenitis and infiltrate cell phenotypes in vivo in MRL/lpr mice with specific anti-TCR V beta MoAb treatment.